ClinicalTrials.gg
RecruitingNCT06964438POEMS2Updated Jun 15, 2026

Postoperative Electrical Muscle Stimulation Two

An interventional study of Neuromuscular Electrical Stimulation and Protein supplement drink in Surgery, Colorectal Cancer and Muscle Atrophy, sponsored by University of Nottingham. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-15.

Sponsored by University of Nottingham · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 388 studies in Colorectal Neoplasms with a site in United Kingdom — 72 open to participants now, 100 under way, 18 of them phase 3. Colorectal Neoplasms · United Kingdom.

Planned enrollment
232nd of 299
45 · median 150
Started
2025
with 19 others
No phase
64 of 388
12 open now
Primary completion
2027-02
later than 44 of 99 live
Registered
367th of 388
by date

Among the 388 studies in Colorectal Neoplasms with a site in United Kingdom, this one is the 232nd largest by planned enrollment of the 299 interventional ones that give a count, is one of 20 that started in 2025, is one of 64 with no phase, reaches primary completion later than 44 of the 99 other live ones, and was the 367th registered.

Colorectal Neoplasms

6,555 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

72 of the 388 studies in Colorectal Neoplasms with a site in United Kingdom are open now. Recruiting first, the newest first:

67 more — sign in →

All 72 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 388 studies in Colorectal Neoplasms with a site in United Kingdom, or all of them as a file.
02

Study summary

Undesirable loss of skeletal muscle mass (atrophy) is a common feature of many diseases as well as ageing, bed rest and physical inactivity. Losing muscle can lead to a reduction in one's ability to perform physical activities, and reduce independence and overall health. Muscle mass loss occurs very quickly (i.e., within a few days) after surgery.

The investigators previous work has shown that neuromuscular electrical stimulation (NMES) of the thigh muscles on one side of the body can help maintain muscle mass and strength on the stimulated side after surgery. Since then, additional work has been carried out to find the most effective form of stimulation to build muscle.

The current study aims to use this refined stimulation protocol in a clinical trial on the wards after major abdominal surgery. The intervention will involve delivering stimulation to both thighs in the few days after surgery, so that the investigators can assess whether this stimulation can preserve muscle mass and strength, and also, patients' ability to perform physical activities after surgery. In addition, the study will aim to find out whether any benefit provided by electrical stimulation can be increased further by taking a protein supplement at the same time.

Read the detailed description

The main objective of this trial is to assess whether neuromuscular stimulation (NMES) can minimise muscle loss following abdominal surgery for cancer; and whether such effect is further improved by simultaneous protein supplementation.

The main questions it aims to answer are:

  • Does NMES training reduce the volume of muscle lost from the vastus lateralis (VL) muscle (in the thigh) after surgery as measured on ultrasound scan 5 days after surgery?
  • Does NMES training together with protein supplementation lead to greater reduction of VL muscle volume loss on ultrasound 5 days after surgery then NMES alone?

Researchers will allocate participants into three groups (using a randomisation software).

All participants will visit the hospital once before surgery for starting point measurements including ultrasound.

Whilst they are in hospital, from the first until the fourth day after surgery, they will have the following interventions:

  • Group 1 (the control group) will receive usual post-operative care with no additional interventions;
  • Group 2 will receive normal postoperative care and twice daily NMES training sessions and a flavoured (placebo) drink
  • Group 3 will receive normal post operative care as well as twice daily NMES training sessions and two protein rich drinks per day.

On the fifth day after surgery all participants will have repeat measurements including ultrasound to assess the extent of muscle loss they had since surgery.

03

Conditions studied

  • Surgery
  • Colorectal Cancer
  • Muscle Atrophy
  • Cancer Gi

Keywords

  • electrical stimulation
  • neuromuscular electrical stimulation
  • NMES
  • rehabilitation
  • general surgery
  • colorectal surgery
  • laparotomy
  • laparoscopy
  • postoperative recovery
  • gastrointestinal cancer
  • gastrointestinal surgery
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (age 18 or over at the time of diagnosis made at MDT (multi-disciplinary team meeting)
  • MDT outcome of colorectal or gastric cancer or non-invasive neoplasia (tissue-proven, or radiologically diagnosed and clinically suspected) with the intention to treat with curative abdominal surgery
  • Agreed management plan for open or minimally invasive (laparoscopic or robot assisted) segmental abdominal (colonic or gastric) resection at the Royal Derby Hospital
  • Sufficient mobility and fitness to complete normal ERAS (enhanced recovery after surgery) protocols following surgery
  • Basic conversational spoken English language
  • Ability to give

Exclusion criteria

Exclusion Criteria:

  • Upper GI (gastrointestinal) cancer requiring thoracotomy/thoracoscopy
  • Pre-existing neuromuscular disease (including Parkinsons disease)
  • Pacemaker, implantable cardiac defibrillator or other implanted nerve stimulator device
  • Metal prostheses or other metal-work in either upper legs (hip/knee/femur)
  • Dementia or other cognitive problem or language barrier causing an inability to follow instructions and operate NMES machine
  • Inability to give
  • Disability preventing completion of ERAS after surgery (requiring Zimmer frame/wheeled frame/wheelchair to mobilise or bed-bound)
  • Peripheral vascular disease
  • Epilepsy
  • Pre-existing diagnosis of chronic kidney disease or estimated \<60 on screening visit
  • Pre-existing diagnosis of liver disease
  • Intubation or intensive care admission during study period (between day 0-5 post-op); (surgical high dependency unit patients will be included)
  • Return to theatre for surgical complication within first 5-days post operation
  • History of rhabdomyolysis
  • Pregnancy
  • Deep vein thrombosis within past 6-months
  • Allergy to whey protein
  • Patient refusal of whey protein products on grounds of dietary requirements or intolerance
  • Participating in another clinical trial concurrently or within the last 6 months
  • Known infection with blood borne virus
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • No intervention
    Group 1 - Control

    Standard postoperative care days 1-4

  • Experimental
    Group 2 - NMES (no protein drink)

    Standard postoperative care days 1-4 PLUS twice daily NMES training sessions PLUS placebo drink twice daily (no protein supplement)

    Device: Neuromuscular Electrical Stimulation

  • Experimental
    Group 3 - NMES + protein drink

    Standard postoperative care days 1-4 PLUS twice daily NMES training sessions PLUS protein drink twice daily

    Device: Neuromuscular Electrical Stimulation · Dietary Supplement: Protein supplement drink

Interventions

  • DeviceNeuromuscular Electrical Stimulation

    Neuromuscular Electrical Stimulation training twice daily (30 minutes per session), during postoperative days 1-4. The training will be carried out using a handheld device. Training will be carried out by the participant themselves, with researcher supervision until independently able to do so.

    Also known as: NMES, electrical stimulation, ES, electrical muscle stimulation, EMS

  • Dietary supplementProtein supplement drink

    Whey protein isolate drink, to provide a total of 60 g protein per day (2 x30 g). The supplement will be provided in a powder form to participants. Participants will be asked to consume the supplement around the time of NMES training.

06

What researchers measure

Primary outcomes

  1. Post-operative vastus lateralis (VL) muscle mass loss

    Vastus lateralis (VL) muscle mass loss as measured on ultrasound cross sectional area

    Time frame: Pre-operatively and 5 days post-operatively

Secondary outcomes

  1. Post-operative knee extensor strength losses

    Determined by knee-extensor strength via dynamometry.

    Time frame: Pre-operatively and 5 days post-operatively

  2. Post-operative functional losses determined by short physical performance battery standardized physical function assessment tool

    short physical performance battery

    Time frame: Pre-operatively and 5 days post-operatively

  3. Post-operative functional losses determined by Timed Up and Go standardized physical function assessment tool

    Timed up and go,

    Time frame: Pre-operatively and 5 days post-operatively

  4. Post-operative functional losses determined by 6 minute walk test standardized physical function assessment tool

    6 minute walk test

    Time frame: Pre-operatively and 5 days post-operatively

  5. Post-operative changes in muscle architecture as measured by pennation angle

    Pennation angle on VL US

    Time frame: Pre-operatively and 5 days post-operatively

  6. Post-operative changes in muscle architecture as measured by fascicle length

    fascicle length on VL Ultrasound

    Time frame: Pre-operatively and 5 days post-operatively

  7. Post-operative declines in neuromuscular function

    Determined via surface electromyography

    Time frame: Pre-operatively and 5 days post-operatively

  8. Post-operative loss of independence and quality of life

    Measured using the EuroQoL-5D questionnaire. The EuroQoL-5D-3L questionnaire is a standardised measure of health status developed by the EuroQol Group to provide a simple, generic measure of health for clinical and economic appraisal. It generates a simple descriptive profile and a single summary index value for health status.

    Time frame: Pre-operatively, 5 days post-operatively and 28 days post-operatively

  9. Physical activity profiles of patients following major GI surgery

    Measured using a thigh-worn accelerometer

    Time frame: Days 1-4 post operatively

  10. Circulating amino acid profiles

    Blood samples to assess circulatory amino acid levels

    Time frame: Pre-operatively, and on day 1 and 5 post-operatively

  11. Systemic markers of inflammation

    Blood samples to assess inflammatory marker levels

    Time frame: Pre-operatively, and on day 1 and 5 post-operatively

  12. Post-operative vastus lateralis (VL) muscle mass loss

    Vastus lateralis (VL) muscle mass loss as measured on ultrasound muscle thickness

    Time frame: Pre-operatively and 5 days post-operatively

Other outcomes

  1. Feasibility and acceptability of incorporating NMES into postoperative recovery

    Assessed through compliance and participant feedback questionnaire. The questionnaire will compromise descriptive items rated on a visual analogue scale that has been designed by the researchers to assess various aspects of patient experience with the intervention.

    Time frame: Days 1-4 post-operatively

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Feb 2027, 19 months after the start.

Of 900 non-industry interventional studies with no phase under Colorectal Neoplasms, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 61. This study's planned 19 months is below that.

Counting every sponsor, half of 958 studies reached it within 31 months; a quarter within 14 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2025
First posted
May 9, 2025
StartActual
Jun 5, 2025
Primary completionEst.
Feb 1, 2027
CompletionEst.
Mar 1, 2027
Last update
Jun 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06964438
Collaborators
University Hospitals of Derby and Burton NHS Foundation Trust
Responsible party
Sponsor
First posted
May 9, 2025
Start date
Jun 5, 2025
Primary completion
Feb 1, 2027 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Jun 15, 2026

Study contacts

Sawsan Abdul-Hamid, MBBS
Contact
sawsan.abdul-hamid@nottingham.ac.uk
00441332724687
Beth Phillips, PhD
Contact
beth.phillips@nottingham.ac.uk

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion